Abstract
In rats, 1 mg/kg twice daily for 10 d of nicotine, a nonselective agonist of nicotinic acetylcholine receptors (nAChRs), fails to change α4 and β2 nAChR subunit mRNA but significantly decreased α7 nAChR subunit mRNA and protein expression, which is associated with a 35–40% decrease in the number of 125I-α-Bgtx binding sites in hippocampus. In addition, this schedule of nicotine treatment produced a 40% increase in the number of high- (K D 1 nM), but decreased by 25% the number of low-affinity (K D 30 nM) binding sites for 3H-epibatidine in hippocampus. In contrast, repeated treatment with lobeline (2.7 mg/kg twice daily for 10 d), which selectively binds to high-affinity binding nAChRs, fails to change the expression of high- or low-affinity nAChRs. These data suggest that a simultaneous upregulation of high-affinity nAChRs and downregulation of low-affinity nAChRs is elicited by ligands that can bind to both low- and high-affinity nAChRs, but not by selective agonists of high-affinity nAChRs. One might infer that in hippocampus, high- and low-affinity nAChRs may be located in the same cells. When these two receptor types are stimulated simultaneously by nonselective ligands for high- and low-affinity nAChRs, they interact, bringing about an increase in binding site density of the high-affinity nAChRs.
Similar content being viewed by others
Abbreviations
- nAChR:
-
nicotinic acetylcholine receptor
- α-Bgtx:
-
α-bungarotoxin
- MLA:
-
methyllycaconitine
- RT:
-
reverse transcriptase
- PCR:
-
polymerase chain reaction
- SDS:
-
sodium dodecyl sulfate
- PAGE:
-
polyacrylamide gel electrophoresis.
References
Albuquerque E. X., Alkondon M., Pereira E., Castro G. N., Schrattenholz A., Barbosa C. T. F., et al. (1996) Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 280, 1117–1136.
Banerjee S. and Abood L. J (1989) Nicotine antagonists: Phosphoinositide turn-over and receptor binding to determine muscarinic properties. Med. Pharmacol. 38(17), 261–267.
Benwell M., Balfour D., and Anderson J. (1988) Evidence that tobacco smoking increase the density of (−)-[3H] nicotine binding sites in human brain. J. Neurochem. 50, 1243–1247.
Bhat R. V., Turner S. L., Selvaag S. R., Marks M. J., and Collins A. C. (1991) Regulation of brain nicotinic receptors by chronic infusion. J Neurochem. 56(6), 1932–1939.
Bickford-Wimer P. C., Nagamoto H., Johnson R., Adler L., Egan M., Rose G. M., et al. (1990) Auditory sensory gating in hippocampal neurons: a model system in the rat. Biol. Psychol. 27, 183–192.
Bradford M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.
Breese C. R., Adams C., Logel J., Drebing C., Rollins Y., Barnhart M., et al. (1997) Comparison of the regional expression of nicotinic acetylcholine receptor α7 mRNA and [125I]-α-Bungarotoxin binding in human postmortem brain. J. Comp. Neurol. Oct 27; 387(3), 385–398.
Brioni J. D., Decker M. W., Sullivan J. P. and Arneric S. P. (1997) The pharmacology of (−)-nicotine and novel cholinergic channel modulators. Adv. Pharmacol. 37, 153–211.
Broussolle E. P., Wong D. F., Fanelli R. J., and London E. D. (1989) In vivo binding of 3H-nicotine in the mouse brain. Life Sci. 44, 1123–1132.
Changeux J. P. (1989) Functional architecture and dynamics of the nicotinic acetylcholine receptor: an allosteric ligand-gated ion channel, in: Fidia Research Foundation Award Lectures, vol. 4, Raven, NY, pp. 21–168.
Cohen J. B., Weber M., and Changeux J. P. (1974) Effects of local anesthetics and calcium on the interaction of cholinergic ligands with the nicotinic receptor protein in Torpedo marmorata. Mol. Pharmacol. 10, 904–932.
Damaj M. I., Patrick G. S., Creasy K. R., and Martin B. R. (1997) Pharmacology of Lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 282, 410–419.
Decker M. W., Majchzark M. J., and Arneric S. P. (1993) Effects of Lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. 45, 571–576.
Decker M. W., Brioni J. D., Bannon A. W., and Arneric S. P. (1995) Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implication for CNS therapeutics. Life Sci. 56(8), 545–570.
Freedman R., Hall M., Adler L. E., and Leonard S. (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychol. 38 22–33.
Gallo V., Upson L. M., Hayes W. P., Vyklicky L. Jr., Winters C., and Buonanno A. (1992) Molecular cloning and developmental analyses of a new glutamate receptor subunit isoform in cerebellum. J. Neurosci. 12, 1010–1023.
Geertsen S., Afar R., Trifaro J. M., Quik M. (1988) Regulation of α-Bungarotoxin sites in chromaffin cells in culture by nicotinic receptor ligands, K+ and cAMP. Mol. Pharmacol. 34, 549–556.
Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., et al. (1995) Comparative pharmacology of epibatidine: A potent agonist of neuronal nicotine acetylcholine receptors. Mol. Pharmacol. 48, 774–782.
Goldberg S. R., Risner M. E., Stolerman I. P., Reavill C., and Garcha H. S. (1989) Nicotinic and some related compounds: effects on schedule-controlled behavior and discriminative properties in rats. Psychopharmacology 97, 295–302.
Gopalakrishnan M., Buisson B., Touma E., Giordano T., Campbell J. E., Hu I. C., et al. (1995) Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur. J. Pharmacol. Mol. Pharmacol. 290, 237–246.
Grayson D. R., Bovolin P., and Santi M. R. (1993) Absolute quantitation of γ-aminobutyric acidA receptor subunit messenger RNA by competitive polymerase chain reaction. Methods Neurosci. 12, 191–208.
Hollman M. and Heinemann S. (1994) Cloned glutamate receptors. Ann. Rev. Neurosci. 17 31–108.
Lecca D., Shim I., Costa E., and Javaid J. I. (1999) Striatal application of nicotine, but not lobeline attenuates dopamine release. Neuropharmacology (in press).
Lendvai B., Sershen H., Lajtha A., Santha E., Baranyi M., and Vizi E. S. (1996) Differential mechanisms involved in the effect of nicotinic agonists DMMP and Lobeline to release [3H]5-HT from rat hippocampal slices. Neuropharmacology 35(12), 1769–1777.
Leonard S., Adams C., Breese C. R., Adler L. E., Bickford P., Byerley W., et al. (1996) Nicotinic receptor function in schizophrenia. Schizophrenia Bull. 22, 431–445.
Lindstrom J. (1996) Neuronal nicotinic acetylcholine receptors. Ion Channels 4, 377–449.
Marks M. J., Burch J. B., and Collins A. C. (1983) Effects of chronic nicotine infusion on tolerance development and nicotine receptors. J. Pharmacol. Exp. Ther. 226, 817–825.
Marks M. J., Stitzel J. A., and Collins A. C. (1985) Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J. Pharmacol. Exp. Ther. 235(3), 619–628.
Marks M. J., Stitzel J. A., Romm E., Wehner J. M., and Collins A. C. (1986) Nicotinic binding sites in rat and mouse brain. Comparison of acetylcholine, nicotine and alpha-Bungarotoxin. Mol. Pharmacol. 30, 427–436.
Marks M. J., Pauly J., Gross D., Deneris E., Hermans-Borgmeyer I., Heinemann S., et al. (1992) Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 12, 2765–2784.
McLane K. E., Wu X., Lindstrom J. M., and Conti-Tronconi B. M. (1992) Epitope mapping of polyclonal and monoclonal antibodies against two α-bungarotoxin binding α-subunits from neuronal nicotinic receptors. J. Neuroimmunol. 38, 115–128.
McPherson G. I. (1987) Ligand (release 2.0), Elsevier Biosoft, Cambridge.
Messing A. (1982) Cholinergic agonist-induced down-regulation of neuronal (−)bungarotoxin. Brain Res. 232, 479–484.
Nicoletti F., Wroblewski J. T., Novelli A., Alho H., Guidotti A., and Costa E. (1986) The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells. J. Neurosci. 6, 1905–1911.
Orr-Utreger A., Goldner F. M., Saeki M., Lorenzo I., Golberg L., De Biasi M., et al. (1997) Mice deficient in the α7 neuronal nicotinic acetylcholine receptor lack α-bungarotoxin binding sites and hippocampal fast nicotine currents. J. Neurosci. 17, 9165–9171.
Peng X., Gerzanich V., Anand R., Wang F., and Lindstrom J. (1997) Chronic nicotine treatment upregulates α3 and α7 acetylcholine receptor subtypes expressed by human neuroblastoma cell line SH-SY5Y. Mol. Pharmacol. 51, 776–784.
Perry D. C., Davila-Garca M. I., Musachio J. L., and Kellar K. J. (1997) Epibatidine analogs label subpopulation of neuronal nicotinic receptors. Soc. Neurosci. Abstracts 1, 154.12.
Rao T. S., Correa L. D., and Lloyd G. K. (1997) Effects of lobeline and DMPP on NMDA-evoked acetylcholine release in vitro: Evidence for lack of involvement of classical neuronal nicotinic acetylcholine receptors. Neuropharmacology 36(1), 39–50.
Reavill C., Jenner P., Kumar R., and Stolerman I. P. (1988) High affinity binding of [3H](−)-nicotine to rat brain membranes and its inhibition by analogs of nicotine. Neuropharmacologhy 27, 235–241.
Rollins Y. D., Stevens K. E., Harris K. R., Hall M. E., Rose G. M., and Leornard S. (1993) Reduction in auditory gating following intracerebroventricular application of α-bungaratoxin binding site ligands and α7 antisense oligonucleotide. Soc. Neurosci. Abstracts 19, 837.
Rowell P. P. and Li M. (1997) Dose-response relationship for nicotine-induced up-regulation of rat brain nicotine receptors. J. Neurochem. 68, 1982–1989.
Schwartz R. and Kellar K. (1983) Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 220, 214–216.
Teng L., Crooks P. A., Sonsalla P. K., and Dwoskin L. P. (1997) Lobeline and nicotine evoke [3H] overflow from rat striatal slices preloaded with [3H] dopamine: Differential inhibition of synaptosomal and vesicular [3H] dopamine uptake. J. Pharmacol. Exp. Ther. 280, 1432–1444.
Toro E. D., Juiz J. M., Peng X., Lindstrom J., and Criado M. (1994) Immunocytochemical localization of the α7 subunit of nicotinic acetylcholine receptor in rat central nervous system. J Comp. Neurol. 349, 325–342.
Ulrich Y. M., Hargreaves K. M., and Flores C. M. (1997) A comparison of multiple injection versus continuous infusion of nicotine for producing upregulation of neuronal [3H]-epibatidine binding sites. Neuropharmacology 36(8), 1119–1125.
Warpman U., Friberg L., Gillespie A., Hellstrom-Lindahl E., Zhang X., and Nordberg A. (1998) Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and Sh-SY5Y neuroblastoma cells. J. Neurochem. 70(5), 2028–2037.
Weber M., David-Pfeuty M. T., and Changeux J. P. (1975) Regulation of binding properties of the nicotinic receptor protein by cholinergic ligands in membrane fragments from Torpedor mamorata. Proc. Natl. Acad. Sci. USA 72, 3443–3447.
Wonnacott S. (1990) The paradox of nicotine acetylcholine receptor up-regulation by nicotine. Trends Pharmacol. Sci. 11, 216–219.
Zoti M., Lena C., Picciotto M. R., and Changeux J. P. (1998) Identification of four classes of brain nicotinic receptors using β2-mutant mice. J. Neurosci. 18, 4461–4472.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Auta, J., Longone, P., Guidotti, A. et al. The regulation of hippocampal nicotinic acetylcholine receptors (nAChRs) after a protracted treatment with selective or nonselective nAChR agonists. J Mol Neurosci 13, 31–45 (1999). https://doi.org/10.1385/JMN:13:1-2:31
Issue Date:
DOI: https://doi.org/10.1385/JMN:13:1-2:31